News
Press ReleaseRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access
Dr. Moody stated: “I look forward to serving as a medical and clinical advisor to Revive for both their FDA Phase 3 study and their expansion initiatives in Canada for clinical studies in COVID-19.”
Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program
Dr. Moody stated: “I look forward to serving as a medical and clinical advisor to Revive for both their FDA Phase 3 study and their expansion initiatives in Canada for clinical studies in COVID-19.”
Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence from in vitro SARS-CoV-2 infection studies.
Dr. Moody stated: “I look forward to serving as a medical and clinical advisor to Revive for both their FDA Phase 3 study and their expansion initiatives in Canada for clinical studies in COVID-19.”
Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor
Dr. Moody stated: “I look forward to serving as a medical and clinical advisor to Revive for both their FDA Phase 3 study and their expansion initiatives in Canada for clinical studies in COVID-19.”
Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics
TORONTO, Nov. 18, 2020 - Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into an exclusive...
Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin
TORONTO, Nov. 11, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on its...